About two months after discontinuing the Phase IIb/III BEACON-IPF study of idiopathic pulmonary fibrosis drug candidate bexotegrast, Pliant Therapeutics announced it’s cutting roughly 45% of its workforce. The move is meant to help extend the San Francisco–based biotech’s cash runway to support execution of late-stage clinical trials. The company, which develops oral integrin inhibitors for fibrotic diseases, did not say how long that runway will last.